Ataraxis AI

Pathology contains extensive data, but whole slide images are large and clinically valuable questions, such as whether a patient will relapse or respond to therapy, cannot be readily inferred from a slide. The relevant signal is subtle and difficult for the human eye to quantify.

Ataraxis AI announced Ataraxis Breast NEO, a new predictive test within its Ataraxis Breast platform designed to estimate the likelihood of pathologic complete response (pCR) following neoadjuvant therapy in patients with early-stage breast cancer.

Ataraxis is presenting data at ASCO 2026 on AI predictions of individual breast cancer treatment benefits for adjuvant and neoadjuvant therapies. The presentation includes clinical validation in a Phase III randomized controlled trial and results from a prospective trial of Ataraxis Breast.

With $20.4m in Series A funding from AIX Ventures, Peter Thiel, and healthcare and AI pioneers, Ataraxis AI is positioned to rapidly bring its first offering, Ataraxis Breast, to market

Ataraxis is a team of artificial intelligence and precision oncology experts, developing novel, advanced AI methodology to predict outcomes through multi-modal data.

Ataraxis offers Ataraxis Breast, Kestrel, and other Ataraxis AI offerings.

Transforming Cancer Care with AI Precision Medicine.

Ataraxis AI, Inc. explains how it collects, stores, uses, shares, transfers, deletes, and processes personal data. For individuals in the European Union, United Kingdom, or European Economic Area, Ataraxis AI, Inc. acts as the data controller for personal data collected.

Ataraxis AI launches Ataraxis Breast NEO, a predictive test for early-stage breast cancer. It estimates the likelihood of pathologic complete response after neoadjuvant therapy across all major subtypes.

Apr 2026 · Business WireNews article

Ataraxis AI launches Ataraxis Breast CTX, a predictive capability within its Ataraxis Breast platform that estimates individualized chemotherapy benefit for breast cancer patients. The test combines digitized H&E pathology slides with clinical data.

Mar 2026 · Business WireNews article

Ataraxis AI and Unicancer announce a strategic collaboration to validate Ataraxis AI's breast cancer platform using large-scale clinical trial data. The collaboration initially focuses on hormone receptor-positive breast cancer, with validation using data from a global Phase III clinical trial.

Jan 2026 · Business WireNews article

Ataraxis AI announced plans to present eight research abstracts featuring Ataraxis Breast data at the 2025 San Antonio Breast Cancer Symposium (SABCS). The presentations include extensive real-world validation and head-to-head comparisons with the previous generation of tests, and are described as expanding the clinical utility of Ataraxis Breast.

Nov 2025 · Business WireNews article